Please discuss any other data in multiple myeloma released at ASCO 2024 that you find noteworthy to share with colleagues.
Outside of ASCO 2024, what ongoing research efforts are you most excited for in the treatment and management of multiple myeloma? What can we look forward to through the end of the year and beyond?

Related Content

Current practices for IV isatuximab administration takes over an hour | image credit: NAMPIX - stock.adobe.com

Rapid IV Isatuximab Could Shift Care Practices in MM

February 13th 2025

Article

Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients with multiple myeloma (MM) and health care systems alike.

cell abnormalities, multiple myeloma | image credit: LASZLO - stock.adobe.com

Prolonged Survival in MM: Insights From the Largest Ongoing US Registry

February 7th 2025

Article

The Connect MM Registry is the longest-running and largest registry in the US, providing invaluable prognostic insights into various patient and disease characteristics.

An Argument for Outpatient Bispecific Antibody Delivery: Dr Kirollos Hanna

January 25th 2025

Article

Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.

Robert Rifkin, MD | Image credit: Rocky Mountain Cancer Centers

Study of Prophylactic Tocilizumab May Soon Add Talquetamab Arm

January 22nd 2025

Article

High Infection Risk in MM: Insights From the Preimmunotherapy Era

January 21st 2025

Article

Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, novel therapies.

MRD status cannot be detected with a microscope and is achieved through bone marrow analysis | image credit: Arthur Constantine - stock.adobe.com

MRD Negativity: A "Robust" Predictor of Survival Outcomes in MM

January 13th 2025

Article

This meta-analysis sheds more light on the beneficial impact of multiple melanoma (MM) treatments and the predictive value of minimal residual disease (MRD) status for patient prognoses.

Related Content

Rapid IV Isatuximab Could Shift Care Practices in MM

February 13th 2025

Article

Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients with multiple myeloma (MM) and health care systems alike.

Prolonged Survival in MM: Insights From the Largest Ongoing US Registry

February 7th 2025

Article

The Connect MM Registry is the longest-running and largest registry in the US, providing invaluable prognostic insights into various patient and disease characteristics.

An Argument for Outpatient Bispecific Antibody Delivery: Dr Kirollos Hanna

January 25th 2025

Article

Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.

Study of Prophylactic Tocilizumab May Soon Add Talquetamab Arm

January 22nd 2025

Article

High Infection Risk in MM: Insights From the Preimmunotherapy Era

January 21st 2025

Article

Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, novel therapies.

MRD Negativity: A "Robust" Predictor of Survival Outcomes in MM

January 13th 2025

Article

This meta-analysis sheds more light on the beneficial impact of multiple melanoma (MM) treatments and the predictive value of minimal residual disease (MRD) status for patient prognoses.

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777